Lakewood-Amedex Biotherapeutics Inc (LABT) Price Prediction & ForecastLABTLakewood-Amedex Biotherapeutics Inc

Alphio's LABT stock price prediction model matches the current Lakewood-Amedex Biotherapeutics Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $0.28 (-0.01%). The 1-week path is $0.28 (+0.67%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

Lakewood-Amedex Biotherapeutics Inc. (LABT) is not a good buy right now due to its extremely low current price of $0.31, a staggering year-to-date change of -99.70%, and a very low RSI of 7.114 indicating oversold conditions. The company has reported consistent losses, with a net income of -3772008.00 USD in Q2 2026, and a forward P/E ratio of 0, suggesting no earnings growth is expected. Additionally, the stock has seen a 5-day change of -46.55%, reflecting significant downward momentum. The main risk is the company's ongoing financial struggles, as evidenced by its negative EPS of -4.42 and a current ratio of only 0.02, indicating potential liquidity issues.

Lakewood-Amedex Biotherapeutics Inc (LABT) last closed at $0.283, losing -8.71%. These facts feed the 1-day and 1-week LABT price prediction above.